Literature DB >> 22210907

Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression.

Leo Hansmann1, Christian Schmidl, Janina Kett, Lena Steger, Reinhard Andreesen, Petra Hoffmann, Michael Rehli, Matthias Edinger.   

Abstract

CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg) are pivotal for peripheral self-tolerance. They prevent immune responses to auto- and alloantigens and are thus under close scrutiny as cellular therapeutics for autoimmune diseases and the prevention or treatment of alloresponses after organ or stem cell transplantation. We previously showed that human Treg with a memory cell phenotype, but not those with a naive phenotype, rapidly downregulate expression of the lineage-defining transcription factor FOXP3 upon in vitro expansion. We now compared the transcriptomes of stable FOXP3(+) Treg and converted FOXP3(-) ex-Treg by applying a newly developed intranuclear staining protocol that permits the isolation of intact mRNA from fixed, permeabilized, and FACS-purified cell populations. Whole-genome microarray analysis revealed strong and selective upregulation of Th2 signature genes, including GATA-3, IL-4, IL-5, and IL-13, upon downregulation of FOXP3. Th2 differentiation of converted FOXP3(-) ex-Treg occurred even under nonpolarizing conditions and could not be prevented by IL-4 signaling blockade. Thus, our studies identify Th2 differentiation as the default developmental program of human Treg after downregulation of FOXP3.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22210907     DOI: 10.4049/jimmunol.1102288

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Histone methylation mediates plasticity of human FOXP3(+) regulatory T cells by modulating signature gene expressions.

Authors:  Haiqi He; Bing Ni; Yi Tian; Zhiqiang Tian; Yanke Chen; Zhengwen Liu; Xiaomei Yang; Yi Lv; Yong Zhang
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

2.  The transcriptional repressor Bcl6 controls the stability of regulatory T cells by intrinsic and extrinsic pathways.

Authors:  Deepali V Sawant; Hao Wu; Weiguo Yao; Sarita Sehra; Mark H Kaplan; Alexander L Dent
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

Review 3.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 4.  Harnessing FOXP3+ regulatory T cells for transplantation tolerance.

Authors:  Herman Waldmann; Robert Hilbrands; Duncan Howie; Stephen Cobbold
Journal:  J Clin Invest       Date:  2014-04-01       Impact factor: 14.808

5.  Regulatory T Cells in Idiopathic Pulmonary Fibrosis: Too Much of a Good Thing?

Authors:  Meagan W Moore; Erica L Herzog
Journal:  Am J Pathol       Date:  2016-06-23       Impact factor: 4.307

6.  Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

Authors:  Denise L Cecil; Gregory E Holt; Kyong Hwa Park; Ekram Gad; Lauren Rastetter; Jennifer Childs; Doreen Higgins; Mary L Disis
Journal:  Cancer Res       Date:  2014-04-28       Impact factor: 12.701

7.  A Mutation in the Transcription Factor Foxp3 Drives T Helper 2 Effector Function in Regulatory T Cells.

Authors:  Frédéric Van Gool; Michelle L T Nguyen; Maxwell R Mumbach; Ansuman T Satpathy; Wendy L Rosenthal; Simone Giacometti; Duy T Le; Weihong Liu; Todd M Brusko; Mark S Anderson; Alexander Y Rudensky; Alexander Marson; Howard Y Chang; Jeffrey A Bluestone
Journal:  Immunity       Date:  2019-01-29       Impact factor: 31.745

Review 8.  Mechanisms of tolerance induction in allergic disease: integrating current and emerging concepts.

Authors:  J Wisniewski; R Agrawal; J A Woodfolk
Journal:  Clin Exp Allergy       Date:  2013-02       Impact factor: 5.018

9.  B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms.

Authors:  Joseph R Podojil; Linda N Liu; Shannon A Marshall; Ming-Yi Chiang; Gwen E Goings; Lieping Chen; Solomon Langermann; Stephen D Miller
Journal:  J Autoimmun       Date:  2013-05-14       Impact factor: 7.094

10.  Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Authors:  Jeffrey A Bluestone; Jane H Buckner; Mark Fitch; Stephen E Gitelman; Shipra Gupta; Marc K Hellerstein; Kevan C Herold; Angela Lares; Michael R Lee; Kelvin Li; Weihong Liu; S Alice Long; Lisa M Masiello; Vinh Nguyen; Amy L Putnam; Mary Rieck; Peter H Sayre; Qizhi Tang
Journal:  Sci Transl Med       Date:  2015-11-25       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.